Monoamine oxidase inhibitor-responsive depression

Giller, Earl L.; Bialos, Donald; Riddle, Mark A.; Sholomskas, Alan J.; Harkness, Laurie

doi:10.1016/0165-1781(82)90036-1

Cited by 27 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GOM is a relatively new technique, and further studies are therefore of interest. In this report we describe the results of applying this technique to 130 out-patients with depressive illness who took part in a doubleblind trial of isocarboxazid and placebo (Zisook, 1983;Giller et al 1982). This analysis again yielded five pure depressive types, some of which contain many similarities to the pure types described in our previous report.…”

Section: Introductionmentioning

confidence: 88%

See 1 more Smart Citation

Classification of depression by grade of membership: a confirmation study

et al. 1989

View full text Add to dashboard Cite

SYNOPSISOne hundred and thirty out-patients with depression were studied by grade of membership multivariate (GOM) analysis. Five depressive types were generated. Pure Type I represented a mild form of melancholia in older, stable males, who showed a modest drug response. Pure Type II included obsessive-anxious symptoms in older patients who responded well to an MAOI drug, but poorly to placebo. Pure Type III was a mildly symptomatic form of depression which responded well to placebo. Pure Type IV included features of agitation, mood worsening later in the day, anorexia and depersonalization; it was commonly precipitated by external stress and MAOI treatment was more effective than placebo. In Pure Type V depression, patients were mostly younger females with high levels of symptomatology, atypical vegetative symptoms, unstable life-styles, disadvantaged backgrounds and a poor response to MAOI and placebo. These results resemble in many ways our earlier GOM study of depression, as well as other multivariate studies of depression in the literature.

show abstract

Section: Introductionmentioning

confidence: 88%

“…One hundred and thirty patients entered doubleblind treatment in this multicentre trial, the criteria for which are described elsewhere (Zisook, 1983;Giller et al 1982).…”

Section: Methodsmentioning

confidence: 99%

Classification of depression by grade of membership: a confirmation study

et al. 1989

View full text Add to dashboard Cite

show abstract

“…6 The efficacy of isocarboxazid in the treatment of predominantly atypical and/or treatment-resistant depression was established via a series of randomized controlled trials conducted in the 1980s and early 1990s. [7][8][9][10][11] Accordingly, isocarboxazid-along with other monoamine oxidase inhibitors-is recommended for these indications in many national and international guidelines, [12][13][14][15][16] typically as a last (pharmacological) resort.…”

mentioning

confidence: 99%

Treatment History Characteristics Associated With Use of Isocarboxazid

Holm

Larsen

Ishtiak‐Ahmed

et al. 2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

Purpose/BackgroundThe monoamine oxidase inhibitor isocarboxazid (Marplan) is occasionally used in the treatment of depression, but there is only little knowledge on the nature of the use of isocarboxazid in clinical practice. We aimed to identify treatment history characteristics associated with this use.Methods/ProceduresVia the nationwide Danish registers, we identified all adult incident users of isocarboxazid in the period from 2001 to 2018, as well as up to 5 matched controls using another antidepressant (matched on date of redeemed prescription, age, sex, and region of residence). The 5-year treatment history of the isocarboxazid users and the controls was assessed via the Danish registers. The association between treatment history characteristics and isocarboxazid use was examined by multivariate conditional logistic regression.Findings/ResultsWe identified 1455 isocarboxazid users and 7045 controls using another antidepressant. The following characteristics were associated with statistically significant increased likelihood of receiving isocarboxazid treatment: Prior treatment with a selective serotonin reuptake inhibitor (odds ratio [OR], 1.80 with 95% confidence interval [CI], 1.46–2.23), a serotonin-norepinephrine reuptake inhibitor (OR, 4.90; 95% CI, 4.08–5.89), a noradrenergic and specific serotonergic antidepressant (OR, 1.56; 95% CI, 1.30–1.88), a tricyclic antidepressant (OR, 5.05; 95% CI, 4.19–6.08), other antidepressants (OR, 4.74; 95% CI, 3.74–6.01), lithium (OR, 6.70; 95% CI, 5.08–8.83), an antipsychotic (OR, 1.43; 95% CI, 1.19–1.73), and each diagnosis of depression received in relation to psychiatric hospital treatment (OR, 1.31; 95% CI, 1.23–1.39). Forty percent of those initiating isocarboxazid had received treatment with drugs from 5 or more different psychopharmacological classes in the 5 preceding years.Implications/ConclusionsThese findings suggest that isocarboxazid is typically used for treatment-resistant depression, consistent with guideline recommendations.

show abstract